PriceTargets.com logo

POINT Biopharma Global - PNT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.80
  • Forecasted Upside: 2.40%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.50 As of 12/27/2023 09:00 PM ET
▲ +0.02 (0.16%)
Get New POINT Biopharma Global Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PNT

Analyst Price Target is $12.80
▲ +2.40% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for POINT Biopharma Global in the last 3 months. The average price target is $12.80, with a high forecast of $14.00 and a low forecast of $12.50. The average price target represents a 2.40% upside from the last price of $12.50.

This chart shows the closing price for PNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in POINT Biopharma Global. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2023Brookline Capital ManagementReiterated RatingBuy ➝ Hold$27.00 ➝ $12.50Low
10/24/2023Piper SandlerReiterated RatingOverweight ➝ Neutral$12.50Low
10/6/2023Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
10/6/2023SVB LeerinkDowngradeOutperform ➝ Market PerformLow
10/5/2023Raymond JamesDowngradeOutperform ➝ Market Perform$13.00 ➝ $12.50Low
10/4/2023JonestradingReiterated RatingBuy ➝ HoldLow
10/4/2023GuggenheimDowngradeBuy ➝ NeutralLow
10/3/2023William BlairDowngradeOutperform ➝ Market PerformLow
10/3/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
10/3/2023Truist FinancialDowngradeBuy ➝ Hold$13.00 ➝ $12.50Low
8/28/2023Raymond JamesSet TargetOutperform$13.00Low
7/20/2023Jefferies Financial GroupReiterated RatingBuy ➝ Buy$12.00 ➝ $14.00Low
6/21/2023Piper SandlerBoost Target$14.00 ➝ $16.00Low
6/1/2023Raymond JamesBoost TargetOutperform$11.00 ➝ $13.00Low
3/7/2023Raymond JamesBoost TargetOutperform$10.00 ➝ $11.00Low
12/14/2022Raymond JamesInitiated CoverageOutperform$10.00Low
11/30/2022SVB LeerinkInitiated CoverageOutperform$14.00Low
11/17/2022OppenheimerLower Target$15.00Low
11/15/2022Truist FinancialLower TargetBuy$22.00 ➝ $14.00Low
11/14/2022Piper SandlerLower Target$17.00 ➝ $14.00Low
10/10/2022OppenheimerInitiated CoverageOutperform$20.00Low
9/18/2022Piper SandlerLower Target$19.00 ➝ $17.00Low
9/15/2022Truist FinancialInitiated CoverageBuy$22.00Low
9/14/2022Berenberg BankInitiated CoverageBuy$20.00Low
9/12/2022GuggenheimBoost Target$20.00 ➝ $22.00Low
9/11/2022Piper SandlerBoost Target$14.00 ➝ $19.00Low
9/6/2022JonestradingInitiated CoverageBuyLow
8/16/2022GuggenheimInitiated CoverageBuy$20.00Low
7/6/2022William BlairInitiated CoverageOutperformN/A
5/26/2022Jefferies Financial GroupUpgradeHold ➝ Buy$7.00 ➝ $20.00Low
5/13/2022Piper SandlerLower TargetNA$17.00 ➝ $14.00Low
12/17/2021MizuhoInitiated CoverageUnderperform$65.00High
12/1/2021Brookline Capital AcquisitionInitiated CoverageBuy$23.00Low
12/1/2021Brookline Capital ManagementReiterated RatingBuy$23.00Medium
7/29/2021CowenInitiated CoverageOutperformHigh
7/27/2021Jefferies Financial GroupInitiated CoverageHold$8.00Low
7/26/2021Piper SandlerInitiated CoverageOverweight$17.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
10/28/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
POINT Biopharma Global logo
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $12.50
Low: $12.49
High: $12.51

50 Day Range

MA: $12.98
Low: $12.45
High: $14.23

52 Week Range

Now: $12.50
Low: $6.57
High: $14.35

Volume

3,290,900 shs

Average Volume

1,442,213 shs

Market Capitalization

$1.33 billion

P/E Ratio

13.89

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of POINT Biopharma Global?

The following Wall Street analysts have issued research reports on POINT Biopharma Global in the last twelve months: Brookline Capital Management, Guggenheim, Jefferies Financial Group Inc., Jonestrading, Leerink Partnrs, Piper Sandler, Raymond James, SVB Leerink LLC, Truist Financial Co., and William Blair.
View the latest analyst ratings for PNT.

What is the current price target for POINT Biopharma Global?

5 Wall Street analysts have set twelve-month price targets for POINT Biopharma Global in the last year. Their average twelve-month price target is $12.80, suggesting a possible upside of 2.4%. Jefferies Financial Group Inc. has the highest price target set, predicting PNT will reach $14.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $12.50 for POINT Biopharma Global in the next year.
View the latest price targets for PNT.

What is the current consensus analyst rating for POINT Biopharma Global?

POINT Biopharma Global currently has 10 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PNT, but not buy more shares or sell existing shares.
View the latest ratings for PNT.

What other companies compete with POINT Biopharma Global?

Other companies that are similar to POINT Biopharma Global include Gyre Therapeutics, Ironwood Pharmaceuticals, ANI Pharmaceuticals, Verona Pharma and Arcus Biosciences. Learn More about companies similar to POINT Biopharma Global.

How do I contact POINT Biopharma Global's investor relations team?

POINT Biopharma Global's physical mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The company's listed phone number is 64-7812-2417. The official website for POINT Biopharma Global is www.pointbiopharma.com. Learn More about contacing POINT Biopharma Global investor relations.